Syneos Health Communications appoints six senior specialists

Syneos Health Communications announced it’s hiring six senior specialists with the goal of expanding its leading market access and external affairs offerings. Among the hires, Mark Sudwell will join as head of value, access and reputation communications.

Fishawack Health hires Deborah Keller as new chair

Deborah Keller will serve as the new chair of Fishawack Health, a commercialization partner for the life science industry. Keller previously spent 28 years at Covance, where she helped bring the company’s top 50 drugs to market.

Bill McEllen promoted to oversee all Fingerpaint advertising offices

Bill McEllen will oversee all Fingerpaint advertising offices, including Saratoga Springs, Conshy, Phoenix and Cedar Knolls. In addition, Beth Beck will lead Fingerpaint’s Saratoga Springs office and Laura Yoars will lead account services in the Cedar Knolls office.

Michael Grela promoted to EVP at Evoke Kyne

Health communications and PR agency Evoke Kyne announced it has promoted Michael Grela to a newly established role of head of reputation and social impact. In the role, Grela will concentrate on global social impact client engagements.

NACDS announces three moves to expand pro-patient, pro-pharmacy agenda

NACDS has announced that Chris Krese will serve as SVP of Congressional relations and communications, Christie Boutte will serve as SVP of reimbursement, innovation and advocacy and Kathleen Jaeger will be SVP of health and wellness strategy, policy and patient advocacy.

Dr. Julian Harris named chairman and CEO at ConcertoCare

Dr. Julian Harris will serve as chairman and CEO at ConcertoCare, which provides in-home healthcare services to seniors. Previously, Harris was president of CareAllies as well as an adviser to Google Ventures, and he led the healthcare team for the White House Office of Management and Budget.

Richard Kim tabbed as chief commercial officer at Avadel Pharmaceuticals

Avadel Pharmaceuticals has hired Richard Kim as chief commercial officer. In the role, he’ll lead the U.S. commercial launch of once-nightly FT218, a treatment for excessive daytime sleepiness and cataplexy in people with narcolepsy.

Dr. Reed Tuckson appointed to Adverum board of directors

Dr. Reed Tuckson will join the board of directors at Adverum, a gene therapy company that focuses on ocular and rare diseases. Tuckson is a healthcare and policy veteran with a background in senior leadership positions at UnitedHealth Group.